New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
March 7, 2014
08:02 EDTNWBONorthwest receives recommendation to continue with Phase III brain cancer trial
Northwest Biotherapeutics announced, in response to shareholder inquiries, that the Data Safety Monitoring Board has made an unblinded review of the safety data for the company's ongoing international Phase III GBM Trial, and has recommended that the trial continue as planned. The DSMB's review of the efficacy data is still pending.
News For NWBO From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
March 27, 2015
09:02 EDTNWBONorthwest Biotherapeutics reports survival data in patients treated with DCVAX-L
Subscribe for More Information
March 16, 2015
17:28 EDTNWBONorthwest Biotherapeutics files to delay Form 10-K
The company requires additional time to complete its year end procedures. Those procedures could not be completed without incurring undue hardship and expense. The company undertakes the responsibility to file such annual report no later than fifteen days after its original date.

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use